TY - JOUR
T1 - Enhancing MAFLD Care
T2 - Efficacy of a Multidisciplinary Community Intervention on Self-Management and Hepatic Outcomes
AU - Cai, Huan Jing
AU - Liang, Hai Lun
AU - Shi, Lei Yu
AU - Rong, Yi Hui
AU - Li, Jing
AU - Zhang, Yan
AU - Ma, Rui Fang
N1 - Publisher Copyright:
© The Author(s) 2025. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
PY - 2025/1/1
Y1 - 2025/1/1
N2 - Metabolic-associated fatty liver disease (MAFLD) is a prevalent condition associated with significant hepatic morbidity, yet evidence-based community interventions remain limited. This mixed-methods study first assessed self-management capacity and quality of life (QOL) among MAFLD patients (n = 218) in community settings, revealing suboptimal self-management (mean score 2.84 ± 0.73) and moderate QOL (3.23 ± 0.77), with education level and occupation identified as predictors. Subsequently, a randomized controlled trial (RCT) evaluated a novel community-based multidisciplinary intervention (nutritional counseling, behavioral coaching, clinical monitoring) versus standard education (n = 100). At 3-month follow-up, the intervention group demonstrated clinically significant improvements versus controls: greater weight reduction (−9.76 vs 0.11 kg; P = .028), body mass index (BMI) decrease (−3.01 vs 0.28 kg/m²; P = .006), and QOL enhancement (+8.97 vs. +2.83 points; P = .002). Significant metabolic and hepatic improvements included reduced liver steatosis (controlled attenuation parameter [CAP]: −29 dB/m; P = .001), lower liver enzymes (alanine aminotransferase [ALT]: −12 U/L, P = .039; aspartate aminotransferase [AST]: −5.5 U/L, P = .015), and decreased fasting glucose (−0.97 mmol/L; P = .026). This scalable multidisciplinary model effectively enhances self-management adherence, improves metabolic health and hepatic parameters, and boosts QOL in MAFLD, offering a resource-efficient strategy for reducing chronic disease burden in primary care.
AB - Metabolic-associated fatty liver disease (MAFLD) is a prevalent condition associated with significant hepatic morbidity, yet evidence-based community interventions remain limited. This mixed-methods study first assessed self-management capacity and quality of life (QOL) among MAFLD patients (n = 218) in community settings, revealing suboptimal self-management (mean score 2.84 ± 0.73) and moderate QOL (3.23 ± 0.77), with education level and occupation identified as predictors. Subsequently, a randomized controlled trial (RCT) evaluated a novel community-based multidisciplinary intervention (nutritional counseling, behavioral coaching, clinical monitoring) versus standard education (n = 100). At 3-month follow-up, the intervention group demonstrated clinically significant improvements versus controls: greater weight reduction (−9.76 vs 0.11 kg; P = .028), body mass index (BMI) decrease (−3.01 vs 0.28 kg/m²; P = .006), and QOL enhancement (+8.97 vs. +2.83 points; P = .002). Significant metabolic and hepatic improvements included reduced liver steatosis (controlled attenuation parameter [CAP]: −29 dB/m; P = .001), lower liver enzymes (alanine aminotransferase [ALT]: −12 U/L, P = .039; aspartate aminotransferase [AST]: −5.5 U/L, P = .015), and decreased fasting glucose (−0.97 mmol/L; P = .026). This scalable multidisciplinary model effectively enhances self-management adherence, improves metabolic health and hepatic parameters, and boosts QOL in MAFLD, offering a resource-efficient strategy for reducing chronic disease burden in primary care.
KW - hepatic outcomes
KW - metabolic-associated fatty liver disease
KW - multidisciplinary community intervention
KW - quality of life
KW - self-management
UR - https://www.scopus.com/pages/publications/105019680498
UR - https://www.scopus.com/pages/publications/105019680498#tab=citedBy
U2 - 10.1177/00469580251380071
DO - 10.1177/00469580251380071
M3 - Article
C2 - 41137547
AN - SCOPUS:105019680498
SN - 0046-9580
VL - 62
JO - Inquiry (United States)
JF - Inquiry (United States)
M1 - 00469580251380071
ER -